Related references
Note: Only part of the references are listed.The Influence of Interleukin-2 Gene Polymorphisms on the Risk and Clinical Outcome of Non-Hodgkin Lymphoma
Somaia Mohammed Mousa et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2021)
Imaging Updates to Breast Cancer Lymph Node Management
Hannah L. Chung et al.
RADIOGRAPHICS (2021)
Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools
Maria Adele Marino et al.
ONCOLOGIST (2020)
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI
Amy S. Ruppert et al.
BLOOD (2020)
Does lymph node morphology using ultrasound reflect aetiology? A pictorial essay, part I
Corinna Trenker et al.
MEDICAL ULTRASONOGRAPHY (2020)
Secreting Germ Cell Tumors of the Central Nervous System: A Long-Term Follow-up Experience
Veronica Biassoni et al.
CANCERS (2020)
ABTB2Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
Yajie Gong et al.
FRONTIERS IN ONCOLOGY (2020)
Stress-induced premature senescence activated by the SENEXgene mediates apoptosis resistance of diffuse large B-cell lymphoma via promoting immunosuppressive cells and cytokines
Jiyu Wang et al.
IMMUNITY INFLAMMATION AND DISEASE (2020)
Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients
Gisele R. Gouveia et al.
BMC CANCER (2020)
Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors associated with non-compliance
M. J. Moesker et al.
THROMBOSIS JOURNAL (2019)
Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis
Mengxi Li et al.
DISEASE MARKERS (2018)
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
Joyoti Dey et al.
SCIENTIFIC REPORTS (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
A. Younes et al.
ANNALS OF ONCOLOGY (2017)
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum 2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model
Yiming Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
Seok Jin Kim et al.
LANCET ONCOLOGY (2016)
Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients
Tarec Christoffer El-Galaly et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene
Reiko Yoshino et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
The Role of Angiogenesis in Human Non-Hodgkin Lymphomas
Domenico Ribatti et al.
NEOPLASIA (2013)
State-of-the-Art Research on Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response
Lale Kostakoglu et al.
FRONTIERS IN ONCOLOGY (2013)
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
Anamarija M. Perry et al.
BLOOD (2012)
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
L. Lee et al.
ANNALS OF ONCOLOGY (2011)
Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival-A Study From the Groupe d'Etude des Lymphomes de l'Adulte
Emmanuel Bachy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
What is remission in follicular lymphoma and what is its relevance?
R Buckstein et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
H Tilly et al.
BLOOD (2003)
Share Paper
